Abstracts tagged "Cutaneous"

Abstract Number: 2451 • ACR Convergence 2025
Tofacitinib Lowers Markers of Photosensitivity in Patients with Cutaneous Lupus Erythematosus
Amy Hurst¹, Mehrnaz Gharaee-Kermani¹, Yuli Cai², Rachael Bogle³, Lin Zhang¹, Amber Young², Craig Dobry¹, Srilakshmi Yalavarthi¹, Jason S. Knight¹, Johann Gudjonsson², Alex Tsoi³, Patricia Rohan⁴, Angela Kibiy⁵, Karen Boyle⁶, Margie Byron⁷, Laura Baird⁷ and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Holland, OH, ⁴NIH, Bethesda, MD, ⁵NIH/NIAID, Rockville, MD, ⁶Rho, Inc, Durham, NC, ⁷Rho, Inc., Durham, NC
Background/Purpose: Photosensitivity lowers quality of life in patients with cutaneous lupus erythematosus (CLE) and puts patients with systemic lupus erythematosus (SLE) at risk of systemic…
Abstract Number: 0660 • ACR Convergence 2025
Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study
J. Michelle Kahlenberg¹, Victoria Werth², Joerg Wenzel³, John Schwarz⁴, Jinqi Liu⁴ and Brandon Johnson⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in moderate to severe plaque psoriasis, has demonstrated significant improvements in cutaneous manifestations…
Abstract Number: 2408 • ACR Convergence 2025
Direct Medical Cost Burden of Cutaneous Lupus Erythematosus (CLE): A Comparison with Psoriasis, Atopic Dermatitis, and a General Population
Joseph F Merola¹, Catherine Mak², Tiange Tang², Tricia Li², Margaret K Moseley², Janine Gaiha-Rohrbach² and Feng Zeng², ¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²Biogen, Cambridge, MA
Background/Purpose: Cutaneous lupus erythematosus (CLE) is an autoimmune disease primarily manifesting in skin that can significantly impact patients’ quality of life. Current understanding of the…
Abstract Number: 0648 • ACR Convergence 2025
Real World Comparative Use of Anifrolumab in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A Multicenter Cohort Study
Rajaie Namas¹, Sarah Al Qassimi², Rowaida Abdou³, Jawahir Alameri², Reem Alblooshi⁴, Fatima Abdulla⁴, Muriel Ghosn⁴, Amir Malik⁴, Raghda Almaashari⁴, Fulvio Salvo⁴, Mohamed Abuzakouk⁴, Atheer Al Ansari⁵, Hazem Helmy Ali Rifaai⁵, Ahlam Almarzooqi⁶, Asia Mubashir⁷, Ahmed Aldhaheri⁴, Suzan Attar⁸ and Mohamed Elarabi⁹, ¹Cleveland Clinic Abu Dhabi, Detroit, MI, ²Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ³NMC Specialty Hospital Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁴Cleveland Clinic Abu Dhabi, Abu Dhabi, ⁵Mediclinic, Abu Dhabi, United Arab Emirates, ⁶Emirates Health Services, Sharjah, United Arab Emirates, ⁷Cleveland Clinic, Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁸King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia, ⁹Cleveland Clinic Abu Dhabi, Hannon, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiorgan organ damage, and early mortality. Anifrolumab (ANI), a human monoclonal antibody targeting the…
Abstract Number: 2409 • ACR Convergence 2025
Cutaneous Lupus Activity Investigator’s Global Assessment―Revised (CLA-IGA-R) Content Validity: Cutaneous Lupus Erythematosus (CLE) Patient Qualitative Study
Joseph F Merola¹, Weihong Yang², Qianyun Li², Helen Doll³, Jason Randall³, Catherine Barbey⁴ and Feng Zeng², ¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²Biogen, Cambridge, MA, ³Clinical Outcomes Solutions, Folkestone, Kent, United Kingdom, ⁴Biogen, Baar, Switzerland
Background/Purpose: The Cutaneous Lupus Activity Investigator’s Global Assessment-Revised (CLA-IGA-R) is an emerging clinician-reported outcome measure for severity of Cutaneous Lupus Erythematosus (CLE) disease activity, developed…
Abstract Number: 0885 • ACR Convergence 2025
MAIT cell-mediated immune modulation in lupus: antigen-driven expansion as a protective strategy
Grace Crossland¹, lennard Ostendorf², Vianey Chavez¹, Lindsay Mendyka¹, Deepak Rao³ and Sladjana Skopelja-Gardner¹, ¹Dartmouth College, Lebanon, NH, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a leading cause of death for young women, and over 75% of SLE patients experience skin manifestations – cutaneous…
Abstract Number: 2313 • ACR Convergence 2025
From Plaque to Plaque: Bridging Oral and Systemic Inflammation in Psoriasis and PsA
guru Vijay Chagalakondu, Vijaya prasanna Parimi and Pradeep S Anand, ESIC Medical College and Super Specilaity Hospital, hyderabad, Telangana, India
Background/Purpose: Psoriasis and psoriatic arthritis (PsA) are two chronic inflammatory conditions which have similar immunopathological mechanisms which also cause periodontal disease. The association between these…
Abstract Number: 0802 • ACR Convergence 2025
Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study
Eric Morand¹, Victoria Werth², Richard Furie³, Sanjeev Roy⁴, Ruth Fernandez Ruiz⁵, Summer Goodson⁶, Hans Gühring⁷, Flavie Moreau⁶ and David Pearson⁸, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, Eysins, Switzerland, ⁵EMD Serono, Billerica, PA, ⁶EMD Serono, Billerica, MA, ⁷The healthcare business of Merck KGaA, Darmstadt, Germany, ⁸Department of Dermatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Cutaneous manifestations of lupus are highly prevalent and have a significant impact on patients’ physical and mental health and wellbeing; however, no targeted therapy…
Abstract Number: 2147 • ACR Convergence 2025
Elevated fMET and GDF-15 Circulating Levels in Pediatric CNO Patients with Psoriasis Define a Distinct Mitochondrial-Inflammatory Signature
Arpit Rathee¹, Noor Kaur¹, Jorge A. Gonzalez-Chapa², Ryan D. Stultz¹, Emily Deng³, Ian Muse⁴, Yongdong Zhao³ and Christian Lood², ¹University of Washington, Division of Rheumatology, Seattle, WA, ²University of Washington, Division of Rheumatology, Seattle, ³University of Washington, Department of Pediatrics, Seattle Children's Hospital, Seattle, WA, ⁴University of Washington, Department of Pediatrics, Seattle Children's Hospital, Seattle
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is a pediatric autoinflammatory bone disorder marked by sterile skeletal inflammation. A subset of CNO patients presents with comorbid psoriasis,…
Abstract Number: 0244 • ACR Convergence 2025
Effectiveness and safety of Anifrolumab in Non-Systemic Cutaneous Lupus
Carmen Lasa Teja¹, Javier Loricera², Marcos López-Hoyos³, Carmen Bejerano-Herreria⁴, Andrea Estébanez⁵, Mireia Sanmartin Martínez⁶, Marta González-Fernández⁷, Ivan Ferraz Amaro⁸ and Ricardo Blanco⁹, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁵Department of Dermatology, Hospital Universitario Doctor Peset, Valencia, Spain, Valencia, Spain, ⁶Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ⁷Basurto University Hospital, Bilbao, Pais Vasco, Spain, ⁸Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Anifrolumab is a human monoclonal antibody targeting the type I interferon receptor, approved for the treatment of systemic lupus erythematosus (SLE), with demonstrated efficacy…
Abstract Number: 1777 • ACR Convergence 2025
Granzyme B as a regulator of interferon alpha production in cutaneous lupus erythematosus
Touraj Khosravi¹, Ahmed Eldaboush², Darae Kang³ and Victoria Werth², ¹Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Potomac, MD
Background/Purpose: Recent studies have shown that monocytes, macrophages, and conventional DCs, but not plasmacytoid dendritic cells (pDC), are major sources of IFNα in cutaneous lupus…
Abstract Number: 1758 • ACR Convergence 2025
Treg need a MAIT: Investigating the contribution of MAIT cells to impaired UV-induced Treg expansion in lupus photosensitive reactions
Grace Crossland¹, Lindsay Mendyka¹, Vianey Chavez¹, Kaitlyn Dowling¹, Michael Constantinides² and Sladjana Skopelja-Gardner¹, ¹Dartmouth College, Lebanon, NH, ²Scripps, La Jolla
Background/Purpose: Most systemic lupus erythematosus (SLE) patients experience sensitivity to ultraviolet (UV) light, which can trigger disfiguring skin lesions or systemic flares. In healthy skin,…
Abstract Number: 1720 • ACR Convergence 2025
Comparison of Mortality Trends in Adults with Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A 21-Year Analysis Using CDC WONDER DATABASE.
Khadija Mohib¹, Rameez Qasim², Zaiya Waseem³, Shaheer Ahmad⁴ and Ahmad Ali Hussain⁵, ¹Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, ²Allama Iqbal Medical College Lahore, Lahore, Pakistan, ³AtlantiCare Regional Medical Center, New Jersey, ⁴Allama Iqbal Medical College, Lahore, Pakistan, ⁵Allama Iqbal Medical College Lahore, Lahore
Background/Purpose: Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE) are chronic autoimmune diseases with significant morbidity and mortality, collectively accounting for approximately 5,000 deaths…
Abstract Number: 1518 • ACR Convergence 2025
Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature
Ali Ali¹, Neelay Purohit², Ciji Robinson², Amanda Darzi³ and Alireza Meysami⁴, ¹Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Canton, MI, ²Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Detroit, MI, ³Department of Internal Medicine, Henry Ford Health System, Detroit, MI, ⁴Henry Ford Health, Detroit, MI
Background/Purpose: Anifrolumab, a monoclonal antibody targeting the type I interferon receptor, demonstrated clinical efficacy in systemic lupus erythematosus in the pivotal TULIP-2 trial¹. However, its…
Abstract Number: 1414 • ACR Convergence 2025
Multidimensional Assessment to Differentiate Early Psoriatic Arthritis from Cutaneous Psoriasis
Eugeniu Russu¹, Victor Cazac², Mircea Betiu³, Alesea Nistor³ and Liliana Groppa⁴, ¹"Nicolae Testemitanu" State Medical and Pharmaceutical University; ”Timofei Moșneaga” Republican Clinical Hospital, Chisinau, Moldova, ²Norwalk Hospital, Nuvance Health, Connecticut, ³State Medical and Pharmaceutical University ”Nicolae Testemițanu”, Chisinau, Chisinau, Moldova, ⁴State Medical and Pharmaceutical University ”Nicolae Testemițanu”, Chisinau, Moldova
Background/Purpose: Psoriatic arthritis (PsA) develops in ~20-30% of psoriasis patients. However, early PsA diagnosis is challenging due to heterogeneous, subtle symptoms and overlap with psoriasis…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].